India called for the creation of a global system that would guarantee timely access to vaccines, diagnostic tools, medicines, and technologies developed based on shared pathogens and biological resources for countries participating in the exchange during a public health emergency.
Similar stories
Methods for Protecting Websites from Automated Attacks
Every day, millions of users interact with various web resources, making purchases, entering credentials, or sending messages. Meanwhile, unnoticed by the average user, thousands of automated programs attempt to hack these sites.
Experts from the cloud provider Reg.oblako explain how specialists in science and engineering have developed systems that allow distinguishing between legitimate visitors and potential attackers. In this context, particular attention is paid to the role of cloud technologies in ensuring security.
Dr Reddy's signs deal to distribute Takeda's dengue vaccine Qdenga in India
Dr Reddy's Laboratories announced on Friday that it has signed an agreement with the Japanese pharmaceutical giant Takeda Pharmaceutical. This agreement provides for the promotion and distribution of the dengue vaccine Qdenga in India.
The deal was signed several months after India's regulator approved the use of Qdenga for both children and adults, making this vaccine the first to receive such approval in the country.
According to Dr Reddy's, the Qdenga vaccine is expected to be available in India in the first half of 2027.
Dengue is a mosquito-borne viral disease and is among the fastest-growing vector-borne diseases globally. The World Health Organization reported a record 14.4 million dengue cases and 11,201 deaths worldwide in 2024. Among these figures, there were 232,425 cases and 233 deaths in India.
The Qdenga vaccine is administered in two doses of 0.5 ml, taken three months apart. The vaccine can be used regardless of previous dengue infection, eliminating the need for pre-vaccination screening.